DrSandeep Grover

An Observational Study of Natural Disease Progression in Adult Participants with Macular Dystrophies Expressing a Stargardt-Type Clinical Presentation.

An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease Secondary to Biallelic Mutation in the ABCA4 Gene

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants with X-Linked Retinitis Pigmentosa

A Randomized Clinical Trial Evaluating Combination Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of Proliferative Diabetic Retinopathy (Protocol AP)

A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 (30 µg and 75 µg) Administered Intravitreally in Participants with Confirmed PRPF31 Mutation Associated Retinal Dystrophy, Including Participants Previously Treated with VP001 in the PLATYPUS Study (Protocol # VP001-101) or WALLABY Study (Protocol # VP001-102) for a Minimum of 8 Weeks

JCHR-DRCR Site 163 CC Fund Addm

A Multicenter, Prospective, Longitudinal, Observational Study in Children and Adults with Stargardt Disease Related Atrophy Secondary to Biallelic Mutations in the ABCA4 Gene

An Observational Study to Assess the Validity of the Ora-VNC and Streetlab MOST-VR Mobility Courses in X-linked Retinitis Pigmentosa

Diabetic Retinopathy and Changes in Lipid Metabolism (Protocol AFA)

A Phase 1 Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

Home OCTGuided Treatment versus Treat and Extend for the Management of Neovascular AMD (Protocol AO)”

A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial in patients with Retinitis Pigmentosa

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated with Rare Disease-Causing Genetic Variants (hereinafter may be referred to as, “Uni-Rare,” “Study,” or “Protocol”)

A Natural History and Outcome Measure Discovery Study of PRPF31 Mutation–Associated Retinal Dystrophy

A Randomized, Controlled, Masked, Multi-center Study Evaluating the Efficacy, Safety, and Tolerability of Two Doses of AGTC-501 Compared to an Untreated Control Group in Male Participants with X-linked Retinitis Pigmentosa

A Phase 1/2 Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) and a Phase 2 Randomized, Controlled, Masked, Multi-center Study Comparing Two Doses of AGTC-501 in Male Participants with X-linked Retinitis Pigmentosa

A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening (Protocol AF)

A Phase 2 Multi-center, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).

STUDY OF COMPARATIVE TREATMENTS FOR RETINAL VEIN OCCLUSION 2(SCORE2)

A Phase 2 Evaluation of Tonabersat for Diabetic Macular Edema (Protocol AN)

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration” 150998-005

STUDY OF COMPARATIVE TREATMENTS FOR RETINAL VEIN OCCLUSION 2(SCORE)

A PHASE 2 DOUBLE MASKED RANDOMIZED CONTROLLED MULTIPLE DOSE REGIMEN RANGING STUDY OF THE EFFICACY AND SAFETY OF ........

Diabetic Retinopathy Clinical Research Network